Advertisement
GSK vs MRK
Which Stock Would AI Choose? GSK plc (GSK) vs. Merck & Co., Inc. (MRK) Stock Comparison
Key Takeaways
- GSK has delivered stronger year-to-date (YTD) performance at +11.45% compared to MRK's +5.50%.
- GSK trades at a lower price-to-earnings (P/E) ratio of 14.42 versus MRK's 15.14, suggesting relative value.
- Both offer attractive dividend yields around 3%, with GSK at 3.27% and MRK at 3.08%.
- MRK boasts a larger market capitalization of $272 billion versus GSK's $108 billion, reflecting broader scale.
- Over the past 12 months, GSK has outperformed MRK with returns of approximately 48% versus 35-40%.
- Analyst price targets indicate upside potential for both, with MRK at $129.74 and GSK at $57.65.
Introduction
This stock comparison examines GSK plc and MRK, two leading pharmaceutical companies focused on vaccines, oncology, and specialty medicines. Investors and traders interested in the healthcare sector may find value in analyzing their relative performance amid ongoing patent dynamics, pipeline advancements, and market volatility. With both stocks offering dividends and growth potential, understanding recent momentum, valuations, and sector exposure aids in assessing stock positioning for diversified portfolios or sector-specific strategies. This analysis draws on current market data to highlight contrasts in a neutral, fact-based manner.
GSK Overview and Recent Performance
GSK plc is a global biopharma leader specializing in vaccines like Shingrix, HIV treatments, and respiratory medicines. Trading around $54 per share with a market cap of $108 billion, it has shown resilience in recent market activity. Year-to-date gains of 11.45% outpace broader indices, supported by strong sales growth and new product launches. In recent weeks, the stock has stabilized near its 52-week high of $61.70, influenced by positive earnings anticipation and analyst upgrades on growth prospects. Sentiment remains buoyed by robust earnings performance and pipeline momentum, though it faces patent cliffs typical in pharma.
MRK Overview and Recent Performance
MRK, or Merck & Co., Inc., dominates in oncology with Keytruda and vaccines, alongside animal health. At approximately $110 per share and a $272 billion market cap, it commands significant scale. YTD return stands at 5.50%, with recent weeks seeing some pullback from highs near $125, amid broader sector rotation. Key drivers include health awareness initiatives and competitive positioning in oncology and vaccines. Upcoming earnings are viewed optimistically by analysts, but sentiment reflects caution on Keytruda competition and market dynamics.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases 25 top-performing AI trading bots curated from over 350 available, optimized for current market conditions across stocks, ETFs, and crypto. These bots employ diverse strategies, including real-time signal agents for copy trading with no minimum balance, virtual agents with customizable risk management, and brokerage agents leveraging live accounts. Timeframes range from 5-minute expert scans to 60-minute intermediate plans, focusing on technical and fundamental analysis amid low to high volatility. Highlighted metrics emphasize promising performance in growth sectors, enabling users to select bots by asset class and style for automated trading. Explore these tools to enhance your strategy in dynamic markets like pharma.
Head-to-Head Comparison
GSK emphasizes vaccines and specialty pharma, contrasting MRK’s oncology-heavy portfolio led by Keytruda. Growth drivers for GSK include Shingrix momentum and HIV franchises, while MRK benefits from broader oncology exposure but faces Keytruda patent risks. Recent momentum favors GSK with superior YTD and 12-month returns, versus MRK’s recent dip. Risk factors are similar—patent expirations and R&D costs—but GSK’s lower P/E offers value trade-off against MRK’s size advantage. Market sentiment leans positive for both ahead of earnings, with sector tailwinds from innovation.
Tickeron AI Verdict
Tickeron’s AI currently leans toward GSK based on trend consistency, relative valuation, and stronger recent momentum. With higher YTD gains, a discounted P/E, and stable performance amid pharma volatility, it shows probabilistic edge over MRK’s scale but softer short-term positioning. Catalysts like earnings could shift dynamics, favoring relative strength plays.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GSK is a StrongBuy and MRK is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GSK’s FA Score shows that 2 FA rating(s) are green whileMRK’s FA Score has 3 green FA rating(s).
- GSK’s FA Score: 2 green, 3 red.
- MRK’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GSK’s TA Score shows that 5 TA indicator(s) are bullish while MRK’s TA Score has 4 bullish TA indicator(s).
- GSK’s TA Score: 5 bullish, 4 bearish.
- MRK’s TA Score: 4 bullish, 6 bearish.
Price Growth
GSK (@Pharmaceuticals: Major) experienced а +3.14% price change this week, while MRK (@Pharmaceuticals: Major) price change was -3.17% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.81%. For the same industry, the average monthly price growth was +7.81%, and the average quarterly price growth was +4.81%.
Reported Earning Dates
GSK is expected to report earnings on Jul 28, 2026.
MRK is expected to report earnings on Aug 04, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+1.81% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| GSK | MRK | GSK / MRK | |
| Capitalization | 107B | 284B | 38% |
| EBITDA | 10.1B | 19.4B | 52% |
| Gain YTD | 8.342 | 10.758 | 78% |
| P/E Ratio | 13.71 | 32.37 | 42% |
| Revenue | 32.8B | 65.8B | 50% |
| Total Cash | 3.44B | N/A | - |
| Total Debt | 19.1B | 49.1B | 39% |
GSK | MRK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 25 | 13 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 9 Undervalued | 10 Undervalued | |
PROFIT vs RISK RATING 1..100 | 37 | 49 | |
SMR RATING 1..100 | 26 | 47 | |
PRICE GROWTH RATING 1..100 | 48 | 23 | |
P/E GROWTH RATING 1..100 | 83 | 5 | |
SEASONALITY SCORE 1..100 | 85 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
GSK's Valuation (9) in the Pharmaceuticals Major industry is in the same range as MRK (10). This means that GSK’s stock grew similarly to MRK’s over the last 12 months.
GSK's Profit vs Risk Rating (37) in the Pharmaceuticals Major industry is in the same range as MRK (49). This means that GSK’s stock grew similarly to MRK’s over the last 12 months.
GSK's SMR Rating (26) in the Pharmaceuticals Major industry is in the same range as MRK (47). This means that GSK’s stock grew similarly to MRK’s over the last 12 months.
MRK's Price Growth Rating (23) in the Pharmaceuticals Major industry is in the same range as GSK (48). This means that MRK’s stock grew similarly to GSK’s over the last 12 months.
MRK's P/E Growth Rating (5) in the Pharmaceuticals Major industry is significantly better than the same rating for GSK (83). This means that MRK’s stock grew significantly faster than GSK’s over the last 12 months.
| GSK | MRK | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 61% | 4 days ago 54% |
| Stochastic ODDS (%) | 4 days ago 37% | 4 days ago 55% |
| Momentum ODDS (%) | 4 days ago 73% | 4 days ago 54% |
| MACD ODDS (%) | 4 days ago 60% | 4 days ago 59% |
| TrendWeek ODDS (%) | 4 days ago 64% | 4 days ago 49% |
| TrendMonth ODDS (%) | 4 days ago 58% | 4 days ago 53% |
| Advances ODDS (%) | 4 days ago 61% | 11 days ago 53% |
| Declines ODDS (%) | 14 days ago 55% | 15 days ago 51% |
| BollingerBands ODDS (%) | 4 days ago 68% | 4 days ago 57% |
| Aroon ODDS (%) | 4 days ago 37% | 4 days ago 64% |
Advertisement
MRK and
Correlation & Price change
A.I.dvisor indicates that over the last year, MRK has been loosely correlated with PFE. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if MRK jumps, then PFE could also see price increases.